Else Nutrition

MIND MEDICINE (NASDAQ: MNMD) STOCK QUOTE

Last Trade: US$7.93 -0.30 -3.65
Volume: 780,472
5-Day Change: 6.16%
YTD Change: 116.67%
Market Cap: US$569.930M

LATEST NEWS FROM MIND MEDICINE

New patent covers MM120 ODT formulation and extends patent term to 2041 Claims include pharmaceutical formulation, methods of manufacturing and methods of treatment for MM120 ODT NEW YORK / Jul 17, 2024 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat mental health disorders, today announced the... Read More
NEW YORK / Jun 28, 2024 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced today that as part of the annual reconstitution of the Russell stock indexes, the Company will be included in the Russell 2000 ® Index and the broad-market Russell 3000 ® Index,... Read More
NEW YORK / Jun 21, 2024 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management team will present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference being held on June 27, 2024. A webcast of the... Read More
NEW YORK / Jun 20, 2024 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the completion of the End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA), supporting the advancement of MM120 (lysergic acid diethylamide [LSD] D-tartrate)... Read More
NEW YORK / May 28, 2024 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management team will participate in the following conferences: BIO International Convention 2024 Panel Name: Challenging Biotech’s One-Track Mind When it... Read More
NEW YORK / May 09, 2024 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management team will participate in the following investor conferences: 2024 RBCCM Global Healthcare Conference Format: Fireside Chat Date and Time:... Read More
GreenStockNews
GAD Diagnosis Increases Healthcare Costs and Decreases Work Productivity and Health-Related Quality of Life People with Undiagnosed GAD Incur Even Higher Total Healthcare Costs than those Diagnosed with GAD Comprehensive Analyses of GAD Disease Burden in the US Conducted by MindMed; Company is Investigating New Treatments for... Read More
Announced positive Phase 2b clinical trial results for MM120 in Generalized Anxiety Disorder (GAD), demonstrating clinically and statistically significant activity through 12 weeks after treatment The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to MM120 for the treatment of GAD in adults Cash and cash equivalents of $252.3 million as of March 31, 2024 Company to host a conference call... Read More
A single oral administration of MM120 100 µg met its primary and key secondary endpoints and maintained clinically and statistically significant HAM-A reductions compared to placebo at 12 weeks with a 65% clinical response rate and a 48% clinical remission rate MindMed also presents two new epidemiology studies quantifying the burden of GAD in the US APA Annual Meeting, the largest psychiatric gathering in the world, is the... Read More
NEW YORK / May 02, 2024 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it plans to host a conference call on Wednesday, May 8, 2024, at 4:30 p.m. ET to provide a corporate update and review the Company’s results for the first quarter ended March 31,... Read More
NEW YORK / Apr 25, 2024 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present detailed results from its phase 2b study of MM120 in Generalized Anxiety Disorder (GAD), as well as multiple presentations describing the epidemiology and growing... Read More
NEW YORK / Apr 02, 2024 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (Cboe Canada: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present posters describing the impact that COVID has had on the epidemiology of Generalized Anxiety Disorder at two upcoming medical conferences:... Read More
All Common shares will remain listed on Nasdaq NEW YORK / Apr 01, 2024 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it has elected to voluntarily delist its common shares from Cboe Canada, effective at the close of markets on... Read More
NEW YORK / Mar 11, 2024 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management team will host one on one investor meetings at the Leerink Partners 2024 Global Biopharma Conference, which will be held in... Read More
NEW YORK / Mar 07, 2024 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the pricing of an underwritten offering of 16,666,667 common shares, no par value per share, at an offering price of $6.00 per common share. In addition, the... Read More
A single oral administration of MM120 100 µg met its key secondary endpoint and maintained a clinically and statistically significant HAM-A reductions compared to placebo at 12 weeks with a 65% clinical response rate and 48% clinical remission rate MindMed plans to hold an End-of-Phase 2 meeting with the U.S. Food & Drug Administration (FDA) in the first half of 2024 and initiate its Phase 3 clinical program in the second... Read More
Data update includes 12-week topline Phase 2b results for MM120 in Generalized Anxiety Disorder (GAD) Results from Phase 1 pharmacokinetics bridging trial for MM120 oral dissolving tablet (ODT) formulation to be discussed NEW YORK / Mar 01, 2024 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (Cboe Canada: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product... Read More
Announced statistically significant and clinically meaningful topline Phase 2b data for MM120 at 4 weeks in Generalized Anxiety Disorder (GAD) Multiple planned milestones for MM120 in GAD, including 12-week Phase 2b data to be presented at March 7th investor event, and initiation of Phase 3 clinical program in second half of 2024 Initiated Phase 1 clinical trial of MM402 in Autism Spectrum Disorder (ASD) Conference call to... Read More
NEW YORK / Feb 22, 2024 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it plans to host a conference call on Wednesday, February 28, 2024, at 8:00 a.m. ET to provide a corporate update and review the Company’s results for the year... Read More
NEW YORK / Feb 07, 2024 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management team will participate in the 34th Annual Oppenheimer Healthcare Life Sciences Conference: 34th Annual Oppenheimer... Read More
Recently announced statistically significant and clinically meaningful topline Phase 2b data for MM-120 in Generalized Anxiety Disorder (GAD) position for multiple data readouts and catalysts throughout 2024 including initiation of Phase 3 clinical program Proof-of-Concept study evaluating repeated sub-perceptual dose (20 μg) of lysergide in adults with Attention-Deficit/Hyperactivity Disorder (ADHD) did not meet primary... Read More
Trial met its primary endpoint with MM-120 demonstrating a statistically significant dose-dependent improvement in HAM-A scores four weeks after a single-dose MM-120 100 µg demonstrated a clinically and statistically significant HAM-A reduction of 21.3 points, representing a 7.6-point improvement over placebo at Week 4 (p=0.0004, Cohen’s d effect size = 0.88) Clinical response rate of 78% in 100 µg and 200 µg dose groups and... Read More
Topline readout of MM-120 in GAD (Phase 2b) expected in Q4 2023 Topline readout of MM-120 in ADHD (Phase 2a proof-of-concept) anticipated by the end of Q1 2024 MM-402 in ASD on track for Phase 1 clinical trial initiation in Q4 2023 Cash and cash equivalents of $117.7 million at September 30, 2023 Company to host conference call today at 4:30 PM ET NEW YORK / Nov 02, 2023 / Business Wire / Mind Medicine (MindMed) Inc.... Read More
NEW YORK / Oct 26, 2023 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it plans to host a conference call on Thursday, November 2, 2023, at 4:30 p.m. ET to provide a corporate update and review the Company’s results for the quarter... Read More
53 participants enrolled across two sites NEW YORK / Oct 24, 2023 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it has completed enrollment of Study MMED007, the Company’s Phase 2a study evaluating repeated low-dose administration of... Read More
Preclinical data in ASD model demonstrate the differences between MM-402 (R-MDMA), S-MDMA and Racemic MDMA with enhanced pro-social effects and reduced hyperactivity NEW YORK / Oct 03, 2023 / Business Wire / Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today the... Read More
NEW YORK / Sep 14, 2023 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that Robert Barrow, Chief Executive Officer of MindMed, will participate in a panel at the TD Cowen 3rd Annual Novel Mechanisms in Neuropsychiatry Summit on Wednesday,... Read More
198 participants dosed across 20 clinical sites On track for topline results in Q4 2023 NEW YORK / Sep 12, 2023 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it has completed enrollment and dosing in Study MMED008, the Company’s Phase 2b... Read More
NEW YORK / Aug 28, 2023 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management team will participate in the following investor conferences: H.C. Wainwright Annual Global Investment Conference Format: Fireside... Read More
Enhances financial flexibility through multiple clinical catalysts on MM-120 and MM-402 product candidates The Company’s ending 2Q2023 cash and cash equivalents of $116.9 million and committed credit facility are expected to fund operations into 2026, if certain milestones are achieved that unlock additional capital $15.0 million drawn at loan closing NEW YORK / Aug 14, 2023 / Business Wire / Mind Medicine (MindMed) Inc.... Read More
Topline readout of MM-120 in GAD (Phase 2b) expected in Q4 2023 with enrollment to be concluded in Q3 2023 Topline readout of MM-120 in ADHD (Phase 2a proof-of-concept) anticipated in Q4 2023 / Q1 2024 MM-402 in ASD on track for Phase 1 clinical trial initiation in Q4 2023 Entered into exclusive license agreement with Catalent for MM-120 Zydis® orally disintegrating tablet (ODT) formulation for advancement into pivotal... Read More
NEW YORK / Aug 03, 2023 / Business Wire / Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it has entered into a license agreement with Catalent, a leader in enabling the development and supply of better treatments for patients worldwide, to access... Read More
NEW YORK / Jul 31, 2023 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or "MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it plans to host a conference call on Thursday, August 3, 2023, at 4:30 p.m. ET to provide a corporate update and review the Company’s results for the quarter ended... Read More
FCM Won the Majority of Retail Shareholders’ Vote and Thanks Them for Their Strong Support FCM Exhorts Institutions to Live Up to Touted Social Investment Goals and Closely Monitor MindMed Board and Management FCM Concerned MindMed Board and Management Will Continue Decimation of Shareholder Value FCM Intends to Continue its Fight for Shareholder Value, and to Hold the Board and Management Accountable for MindMed’s... Read More
NEW YORK / Jun 22, 2023 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management team will participate in the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference: H.C. Wainwright 4th Annual... Read More
NEW YORK / Jun 21, 2023 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), today announced that, based upon a preliminary vote assessment, shareholders have elected all six of the Company’s nominees – CEO Robert Barrow, Dr. Suzanne Bruhn, Dr. Roger Crystal, David Gryska, Andreas Krebs and Carol A. Vallone – to the Board of Directors (the “Board”) at the Annual Meeting of... Read More
NEW YORK / Jun 20, 2023 / Business Wire / Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, will provide an overview of clinical progress and corporate updates during an Investor Day today focused primarily on the MM-120 (lysergide D-tartrate) program in generalized anxiety... Read More
FCM Believes MindMed Is Threatening to Violate NASDAQ Requirements Imperiling MindMed’s Listing and Future Liquidity for Shareholders Failure to Satisfy Quorum Requirement at Annual Meeting Demonstrates Lack of Shareholder Support FCM Believes MindMed’s Announced Plan to Hold Shareholder Meeting Regardless of Level of Shareholder Participation Represents Appalling Corporate Governance Vote on FCM’s BLUE Proxy to Restore... Read More
Meeting Will Resume on Wednesday, June 21, 2023 Believes FCM Has Made Deliberate Efforts to Prevent Quorum from Being Achieved MindMed Encourages Shareholders to Vote FOR All Six of the Company’s Director Candidates on the WHITE Universal Proxy Card NEW YORK / Jun 15, 2023 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), today announced that the Company’s Annual... Read More
Proxy Cards Must be Received by 10:00 AM EDT on Tuesday, June 13 th for Votes to Count Encourages Shareholders to Vote on the WHITE Universal Proxy Card FOR ALL SIX of the Company’s Director Nominees NEW YORK / Jun 09, 2023 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”) today urged shareholders to vote FOR the election of all six of MindMed’s highly qualified director... Read More
Both Leading Proxy Advisory Firms – ISS and Glass Lewis – Now Recommend Support For All MindMed’s Nominees and Concluded FCM Has Not Made a Compelling Case for Change Glass Lewis Notes Company’s Director Nominees Possess the “Appropriate Experience and Qualifications” to Continue Leading MindMed MindMed Encourages Shareholders to Follow ISS and Glass Lewis’s Recommendation and Vote on the WHITE Universal Proxy Card FOR ALL... Read More
FCM Confident in Ability to Start MM-120 Phase III in 2023 and Obtain FDA Approval In 2026 Dr. Freeman and Other FCM Directors Pledge to Extend Lockup Period For Selling Shares Until June 15, 2026 Time is Running Out to Save MindMed Vote on FCM’s BLUE Proxy to Restore Shareholder Value at MindMed SHERIDAN, Wyo., June 07, 2023 (GLOBE NEWSWIRE) -- FCM MM Holdings, LLC ("FCM"), representing approximately 3.5% of the outstanding... Read More
NEW YORK / Jun 07, 2023 / Business Wire / Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that its management team will a host an Analyst Day in New York City on Tuesday, June 20 th , 2023 that will focus on the MM-120 program in generalized anxiety disorder... Read More
VANCOUVER, BC , June 5, 2023 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce Cedar Clinical Research (CCR) is a top research site for MindMed's Phase 2b study evaluating MM-120 (lysergide D-tartrate) for General Anxiety Disorder. CCR's research... Read More
FCM Predicts That the Psychedelic Revolution Will Begin with the FDA’s Likely Groundbreaking Approval of the Drug MDMA, Which is Expected to Occur in the Second Half of 2024 Reiterates that MindMed Must Be Prepared to Leverage this Opportunity FCM’s Plan Will Cut Excessive Spending and Focus Resources on its Flagship Drug LSD (MM-120) FCM Plan Will Have MindMed Start Phase III for MM-120 by End of 2023 and Positioned to... Read More
NEW YORK / Jun 01, 2023 / Business Wire / Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management team will participate in the following investor conferences: BIO International Convention Format: Investor Presentation Date and... Read More
FCM Director Candidates, including Dr. Freeman, and Mr. Jake Freeman, Commit to Not Selling Any of Their MindMed Shares Until June 15, 2025 FCM and its Nominees Stand Behind Their Plan to Drive Value for Shareholders If FCM’s Plan is Enacted, FCM Believes MindMed’s Shares Will be Substantially More Valuable in Two Years Vote on FCM’s BLUE Proxy to Restore MindMed SHERIDAN, Wyo., May 30, 2023 (GLOBE NEWSWIRE) -- FCM MM... Read More
indMed has Slashed Allocation of Spending on Core Drugs While Executive Compensation has Soared to $51M MindMed Phase IIb Clinical Trial Delayed Greenleaf Health Study, Quoting FDA, Supports FCM’s Plan to Immediately Start an LSD Phase III Trial FCM Publishes Presentation Outlining Overwhelming Case for Change at MindMed and Detailing Plan to Bring LSD Drugs to Millions in Need Urges Shareholders to Vote on FCM’s BLUE Proxy... Read More
Details Why MindMed’s Ideally Qualified Nominees Are the Right Choice to Oversee the Company’s Strategic Execution as it Approaches First Clinical Data Readouts Later this Year Urges Shareholders to Protect Their Investments and Vote on the WHITE Universal Proxy Card for ALL SIX of the Board’s Nominees NEW YORK / May 25, 2023 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or... Read More
Independent Third-Party Firm, Led by Former Senior FDA Officials, Calls Phase 2b Trial “Well-designed” and “Essential” Report Further Demonstrates that FCM’s Proposal to Skip Phase 2 for MM-120 – a Cornerstone of its Plan – is Unrealistic and Would Put MindMed Shareholders’ Investments at Risk Visit www.ProtectMindMed.com for More Information NEW YORK / May 25, 2023 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ:... Read More
Preclinical data in ASD model demonstrate prosocial effects of MM-402 NEW YORK / May 24, 2023 / Business Wire / Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today the upcoming presentation of preclinical data of MM-402, the Company’s proprietary form of the... Read More
Over 50% of patients dosed across 20 active clinical sites On Track for Topline Results in late 2023 NEW YORK / May 17, 2023 / Business Wire / Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that the company’s Phase 2b study evaluating MM-120 (lysergide... Read More
FCM Believes MindMed Focused on Pursuing Misguided Clinical Path for MM-120 MindMed Executives, Advisors – Barrow, Karlin, and Liechti – Do Not Have Experience in Bringing Drugs to Market and Are Making Fundamental Errors in Approach MindMed Cash Expected to Run Out in 2024 and Dilution Set to Soar FCM Nominees Have Brought Drugs to Market and Completed Numerous Phase III Trials FCM’s Highly Qualified Nominees Would Start... Read More
MindMed Board has Presided over Botched Regulatory Strategies, Outsized Expenses, Soaring Executive Compensation, and Value Destructive Financings FCM’s Four Highly Qualified Director Nominees to Bring Desperately Needed Accountability, Expertise, and Fresh Shareholder Focused Perspective to the Board Urges MindMed Shareholders to vote FOR All Four of FCM’s Nominees on the BLUE Proxy Card SHERIDAN, Wyo., May 05, 2023 (GLOBE... Read More
Key MM-120 readouts in GAD (Phase 2b) and ADHD (Phase 2a) expected by end of 2023 MM-402 pre-clinical data in ASD model to be presented at ASCP 2023 Annual Meeting Strengthened leadership team with appointment of Mark R. Sullivan as Chief Legal Officer Cash and cash equivalents of $129.4 million at March 31, 2023 Company to host conference call today at 4:30 PM ET NEW YORK / May 04, 2023 / Business Wire / Mind Medicine... Read More
Files Definitive Proxy Materials in Connection with June 15, 2023 Annual Meeting Board’s Nominees Possess Essential Pharmaceutical Industry, Capital Allocation and Corporate Governance Experience Needed to Drive Company’s Success at Pivotal Moment – With Two Key Clinical Readouts Expected Later This Year Believes FCM’s Nominees Lack Relevant Experience and are Unqualified to Serve as MindMed Directors – Let Alone Take... Read More
NEW YORK / May 01, 2023 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or "MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it plans to host a conference call on Thursday, May 4, 2023, at 4:30 p.m. ET to provide a corporate update and review the Company’s results for the quarter ended... Read More
NEW YORK / Apr 26, 2023 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management team will participate in the following investor conferences: H.C. Wainwright BioConnect Conference Format: 1x1 Investor Meetings... Read More
Meaningful Change is Needed at MindMed After Years of Poor Performance FCM’s Candidates Have Decades of Relevant Industry Experience and are Laser Focused on Bringing MM-120 to Market FCM to Provide Detailed Operational Plan to Address MindMed’s Operational Challenges SHERIDAN, Wyo., April 21, 2023 (GLOBE NEWSWIRE) -- Today, FCM MM Holdings, LLC ("FCM") announces that it has filed a preliminary proxy statement (the “Proxy... Read More
Presents Highly Qualified Slate of Director Nominees, Including Five Incumbent Board Members and New Independent Candidate David W. Gryska Highlights Significant Positive Momentum to Advance R&D Pipeline and Enhance Shareholder Value Discloses FCM MM HOLDINGS’ Intent to Take Control of the Board Through Nomination of Four Director Candidates FCM’s Nominees Lack Relevant Industry Expertise and Experience to Drive Long-Term... Read More
Primary endpoint achieved statistically significant improvement in MDD symptoms Confirmation of activity of lysergide in brain health disorders with direct relevance to MindMed’s MM-120 program in Generalized Anxiety Disorder (GAD) Data presented on April 14, 2023 in Basel, Switzerland NEW YORK / Apr 14, 2023 / Business Wire / Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical... Read More
NEW YORK / Apr 13, 2023 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Mark R. Sullivan, effective today, as Chief Legal Officer and Corporate Secretary. “We are very excited to welcome Mark to our management team. Mark... Read More
Company positioned for key MM-120 Phase 2b data readout in GAD and Phase 2a data readout in ADHD in late 2023 Company to initiate first clinical trial of MM-402 in 2023 Cash and cash equivalents of $142.1 million at December 31, 2022 Company to host conference call today at 4:30 PM ET Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or "MindMed"), a clinical stage biopharmaceutical company developing... Read More
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company's management team will participate in the following investor conferences: Cowen 43rd Annual Healthcare Conference Format: Investor Presentation Date and Time: Wednesday, March 8, 2023... Read More
Company positioned for key MM-120 Phase 2b data readout in GAD and Phase 2a data readout in ADHD in late 2023 Company to initiate first clinical trial of MM-402 in 2023 Cash runway to fund current operating plan into first half of 2025 Company to host a virtual analyst and investor day in the first half of 2023 NEW YORK , Jan. 9, 2023 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or... Read More
NEW YORK , Dec. 1, 2022 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that members of the Company's management team will participate in Canaccord Genuity's New Paradigms and Treatment Approaches in Mental Health Conference. Canaccord Genuity New Paradigms and... Read More
SHERIDAN, Wyo., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Today, FCM MM HOLDINGS, LLC (“FCM”) announces that it has sent a letter (the “Letter”) to the Board of Directors (the “Board”) of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) (“MindMed”, the “Company”). On November 10, 2022, MindMed filed with the Securities and Exchange Commission (the “SEC”) form 10-Q for quarter three of 2022 (the “ER”). The Letter focuses on false... Read More
NEW YORK , Nov. 11, 2022 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that members of the Company's management team will participate in the Jefferies London Healthcare Conference, taking place in London, UK from November 15-17, 2022 . Jefferies London... Read More
Initiated Phase 2b dose-optimization trial in patients with Generalized Anxiety Disorder, with first patients dosed in Q3 2022 and key clinical readout expected in late 2023 Advanced IND-enabling studies for MM-402 and initiated Phase 1 investigator-initiated trial in Q3 2022 Cash and cash equivalents of $154.5 million expected to fund current operating plan into first half of 2025 Company to host conference call today at... Read More
Today, FCM MM HOLDINGS, LLC (“FCM”) notifies shareholders that it has formally filed a complaint (the “Complaint”) with the Securities and Exchange Commission (the “SEC”) and will file a referral to the Department of Justice regarding allegations against Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) (“MindMed”, the “Company”). The Complaint focuses on the following allegations: self-dealing, lack of material disclosure, false... Read More
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that it will host its earnings call on Thursday, November 10, 2022 , at 8:30 a.m. EDT to discuss its financial results for the quarter ended September 30, 2022 and provide a business update. Individuals may participate via... Read More
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that members of MindMed's management team will participate in the Cantor Fitzgerald Neurology & Psychiatry Conference, taking place at the Ritz Carlton, San Francisco, CA from October 6-7, 2022 . Cantor Fitzgerald... Read More
Study will compare the acute subjective, physiological, and endocrine effects of R-MDMA, S-MDMA, and racemic MDMA in 24 healthy subjects Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced the initiation of a Phase 1 investigator-initiated trial led by MindMed collaborator... Read More
Investors States Shareholder Requisition of Special Meeting to Effect Significant Change to the Board May be Necessary Today, FCM MM HOLDINGS, LLC ("FCM") announces that it has sent a letter (the "Letter") to the Board of Directors (the "Board") of Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) ("MindMed" or the "Company") informing the Board of FCM's vehement opposition to the Company's public offering announced on September... Read More
Mind Medicine (MindMed) Inc. ("MindMed") (NASDAQ: MNMD) (NEO: MMED), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced the pricing of its underwritten public offering of 7,058,823 common shares, together with accompanying warrants to purchase 7,058,823 common shares. The combined offering price to the public of each common share and accompanying warrant is... Read More
Mind Medicine (MindMed) Inc. ("MindMed") (Nasdaq: MNMD) (NEO: MMED), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that it intends to offer and sell, subject to market conditions, common shares with accompanying warrants to purchase common shares in an underwritten public offering. All of the securities to be sold in the offering will be offered by... Read More
First-in-human trial to investigate the tolerability, pharmacology, and pharmacokinetics of novel MDMA-like compounds versus a placebo in healthy subjects Acute effects of equivalent doses will be compared across the following compounds: MDMA, MDA, Lys-MDMA and Lys-MDA Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products... Read More
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that it has received a letter from The Nasdaq Stock Market LLC advising the Company that it has regained compliance with Nasdaq's minimum bid price listing requirement. The Company has satisfied the terms for continued... Read More
Data from University Hospital Basel (UHB) study supports the clinical development of MindMed's proprietary MM-120 product candidate for Generalized Anxiety Disorder ("GAD") Patient dosing in Phase 2b trial ongoing for MM-120 in GAD MindMed currently owns and retains all clinical data and manufacturing rights for MM-120 and intends to continue broadening its intellectual property portfolio Mind Medicine (MindMed) Inc.... Read More
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that it will participate virtually at the H.C. Wainwright 24th Annual Global Investment Conference, and its presentation will be available beginning at 7:00 a.m. ET on September 12, 2022 . For details or to register to... Read More
Common shares will begin trading on a split-adjusted basis at market open on August 29, 2022 Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that its previously announced 1-for-15 reverse share split of the Company's common shares, par value $0.001 , became effective... Read More
GreenStockNews
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced first patient dosing in its Phase 2b dose-optimization trial of MM-120, a pharmaceutically optimized form of lysergic acid... Read More
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced the appointment of Dr. Suzanne Bruhn and Dr. Roger Crystal , effective August 11, 2022 as independent members of its Board of Directors. "We are pleased to welcome both Dr. Bruhn and Dr. Crystal to our Board. Their collective life... Read More
Phase 2b dose-optimization trial in patients with General Anxiety Disorder underway with first patient dosing expected in Q3 2022 Advanced IND-enabling studies for MM-402 with the Phase 1 investigator-initiated pharmacokinetic/pharmacodynamic trial on track to initiate in Q3 2022 Appoints Drs. Suzanne Bruhn and Roger Crystal as independent members of the Board of Directors Strengthened leadership team with the appointment of... Read More
Today, FCM MM HOLDINGS, LLC ("FCM") announced that it has sent a letter to the Board of Directors of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed") calling on the Board to adopt a new strategic plan proposed by FCM including: refocusing on its core drugs, cutting cash burn, and terminating MindMed's at-the-money equity offering. FCM is directed and managed Dr. Scott Freeman , co-founder and former... Read More
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that its Board of Directors has approved a ratio of 1-for-15 reverse share split of its common shares. As a result of the reverse share split, there will be approximately 28.4 million shares of common shares issued and... Read More
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that it will host its earnings call on Thursday, August 11, 2022 , at 4:30 p.m. EDT to discuss its financial results for the quarter ended June 30, 2022 and provide a business update. Individuals may participate via... Read More
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that members of MindMed's management team will participate in the Canaccord Genuity 42nd Annual Growth Conference, to be held in Boston, MA , August 8-11, 2022 . Canaccord Genuity 42nd Annual Growth Conference Format:... Read More
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED) ("MindMed'' or the "Company") announces that it has completed its previously announced redesignation of its subordinate voting shares as common shares (the "Common Shares") of the Company. The Common Shares will be assigned CUSIP number 60255C802 and ISIN number CA60255C8025 following the redesignation. The Common Shares will begin trading on a post-Redesignation basis... Read More
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), announces the voting results of the Company's annual general and special meeting of shareholders held on June 1, 2022 (the "Meeting"). Election of Directors The five nominees of management were elected as directors at the Meeting. The voting results for the election of each director nominee are as follows: Name of Nominee Votes For Votes... Read More
NEW YORK , June 1, 2022 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that Robert Barrow , Chief Executive Officer and Director, will participate in the Jefferies Global Healthcare Conference, to be held in New York, NY from June 8-10, 2022 . Jefferies Global... Read More
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, announced the appointment of Schond L. Greenway as Chief Financial Officer. Mr. Greenway comes to MindMed with over 20 years of experience in investment banking, finance and corporate advisory, and investment analysis in the life sciences... Read More
Positive safety and tolerability results support the advancement of MM-110 and guide the Phase 2a dose design in individuals undergoing supervised opioid withdrawal Phase 2a trial remains on track to initiate in Q2 2022 Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced... Read More
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED) (the "Company"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, announced today that the registration statement on Form S-3, filed on May 4, 2022 , was declared effective by the U.S. Securities and Exchange Commission, which includes a prospectus for an at-the-market equity offering under which the Company may... Read More
Advanced clinical programs for three lead drug candidates Strengthened leadership team with the appointment of Francois Lilienthal , MD as Chief Commercial Officer Cash runway through key clinical readouts in 2023 and into 2024 Company to host conference call today at 8:30 AM ET Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company"), a clinical stage biopharmaceutical company developing novel products to... Read More
Webinar to feature presentations from Kelly E. Dunn , PhD, MBA, and Stuart Gitlow , MD, MPH, MBA, on Thursday, May 19 at 11:00am EDT Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that it will host a key opinion leader (KOL) webinar on substance use disorders and... Read More
Results from the placebo-controlled investigator-initiated trial, conducted at the University Hospital Basel (UHB), demonstrate the significant, long-lasting beneficial effects of LSD and potential to safely mitigate symptoms of anxiety and depression Data further validates MindMed's therapeutic approach and supports the clinical development of MM-120 for the treatment of Generalized Anxiety Disorder Data was featured in an... Read More
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that it will host its earnings call on Monday, May 16, 2022 , at 8:30 a.m. EDT to discuss its financial results for the quarter ended March 31, 2022 and provide a business update. Individuals may participate via telephone... Read More
GreenStockNews
"LSD as a Treatment for Anxiety Disorders: New Evidence of Efficacy" will present the most recent and robust data on LSD in patients with anxiety This study builds on decades of research on the effects of LSD in humans Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage... Read More
GreenStockNews
Dr. Lilienthal brings over 20 years of global biopharmaceutical experience, leading the development and commercialization of innovative medicines across multiple therapeutic areas including psychiatry and neurology Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), a clinical stage biopharmaceutical company developing... Read More
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, reported a change in auditor for the 2022 fiscal year, subject to the approval of the Company's shareholders at the Company's 2022 annual general and special meeting. The below was reported by MindMed on Form 8-K filed with the U.S.... Read More
GreenStockNews
FDA cleared MindMed's Investigational New Drug (IND) application for Phase 2b dose optimization trial of MM-120 Progressed development programs for all three lead product candidates Cash balance of $133.5 million at year end 2021 Company to host earnings conference call today at 8:30 AM EDT Mind Medicine (MindMed) Inc.... Read More
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that its Chief Financial Officer, David Guebert , will be retiring from his position on March 31, 2022 . "On behalf of the Board of Directors and Executive team, I would like to thank Dave, who was essential to the founding... Read More
GreenStockNews
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that it will host its earnings call on Monday, March 28, 2022 , at 8:30 a.m. EDT to discuss its financial results for the full year ended December 31,... Read More
GreenStockNews
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), a clinical-stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that Robert Barrow , Chief Executive Officer and Director, will participate in the following upcoming investor conferences in March: 34 th Annual Roth... Read More
GreenStockNews
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), a clinical-stage biopharmaceutical company developing psychedelic-inspired therapies for the treatment of brain-based disorders, today announced the peer-reviewed publication of a study directly comparing the acute effects of Lysergic Acid Diethylamide (LSD) and... Read More
GreenStockNews
Automatic conversion to be effective March 14, 2022 Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a clinical-stage biopharmaceutical company developing psychedelic-inspired therapies for the treatment of brain-based disorders, announced today that all the Company's issued and outstanding... Read More
GreenStockNews
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a clinical-stage biopharmaceutical company developing psychedelic-inspired therapies for the treatment of brain-based disorders, announced today that the U.S. Food and Drug Administration (FDA) has cleared MindMed's Investigational New Drug... Read More
GreenStockNews
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a clinical-stage biopharmaceutical company developing psychedelic-inspired therapies for the treatment of mental health and addiction, today announced that it has enrolled the first subjects into its Session Monitoring System (SMS-01) study... Read More
GreenStockNews
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-derived therapies, announces the resignation of Stephen Hurst from his role as a Director of the Company's Board of Directors. "On behalf of MindMed, the Board of Directors, and the Executive... Read More
GreenStockNews
Last subject completed study in late 2021 with topline results expected in early 2022 Results to inform design of Phase 2a study in individuals undergoing supervised opioid withdrawal Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-derived... Read More
GreenStockNews
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, today announced that MindMed's Chief Executive Officer and Director, Robert Barrow , will be participating in a panel and in one-on-one investor meetings at the LifeSci... Read More
GreenStockNews
Bradford Cross , Chief Technology Officer to transition; Don Gehlert , PhD, Chief Scientific Officer to transition to Senior Scientific Advisor Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, today announced that its Chief... Read More
GreenStockNews
FDA has issued a clinical hold on initial IND submission required to initiate Phase 2b trial of LSD for the treatment of generalized anxiety disorder Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, today announced that the... Read More
GreenStockNews
Enrolling patients in proof-of-concept exploratory trial conducted in collaboration with the University Hospital Basel in Switzerland and Maastricht University in the Netherlands Trial led by Dr. Matthias Liechti and Dr. Kim Kuypers , pioneers and leading global experts in the psychedelic landscape Mind Medicine (MindMed) Inc.... Read More
GreenStockNews
Mr. Barrow previously served as interim Chief Executive Officer and Chief Development Officer of MindMed Carol Vallone appointed as Chair of the Board of Directors, Andreas Krebs appointed as Vice Chair and Perry Dellelce transitions from his role as Chairman- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ)... Read More
GreenStockNews
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies recently met with the United States Food and Drug Administration (FDA) Center for Devices and Radiological Health (CDRH) with consultation from the Center for Drug Evaluation... Read More
GreenStockNews
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, today announced that MindMed's Chief Executive Officer, Robert Barrow , will provide a corporate update and the Company's management will participate in one-on-one investor... Read More
GreenStockNews
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, today announced that MindMed's Chief Executive Officer, Robert Barrow , will participate in a panel and Company's management will participate in one-on-one investor meetings... Read More
GreenStockNews
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ); (the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce the publication of the first data on the interaction of the selective serotonin uptake inhibitor (SSRI) escitalopram with the acute response to... Read More
GreenStockNews
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD; NEO: MMED; DE: MMQ; the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce it has launched recruitment for a randomized placebo-controlled study evaluating the effects of daytime and evening administration of repeated low doses of... Read More
GreenStockNews
MindMed (Nasdaq: MNMD, NEO: MMED, DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, has announced its quarterly financial results for the quarter ended September 30, 2021 . Third Quarter 2021 Financial Highlights (in USD) Cash Balance. Total assets as of September 30, 2021 were $178.6 million ,... Read More
GreenStockNews
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that its CEO, Robert Barrow , will be speaking at Jefferies 2021 London Healthcare Conference, taking place on November 16-19 . Management will be... Read More
GreenStockNews
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce the appointment of Maria A. Oquendo , M.D., Ph.D. to its Scientific Advisory Board. Dr. Oquendo is Ruth Meltzer Professor and Chairman of Psychiatry at... Read More
GreenStockNews
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that CEO Robert Barrow will be speaking at Web Summit , taking place on November 1-4, 2021 in Lisbon, Portugal . Barrow will be interviewed at 11:45am... Read More
GreenStockNews
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED), (DE: MMQ); the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce an expansion of its pipeline with the launch of a program to develop R(-)-MDMA for the treatment of social anxiety and functioning in diagnoses that... Read More
GreenStockNews
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that Chief Medical Officer Daniel R Karlin, MD MA, will chair The Digital Biomarkers & Digital Measurements Summit , held virtually on October 26 - 27,... Read More
GreenStockNews
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, has joined the Clinical Trials Transformation Initiative (CTTI) to contribute in developing and driving adoption of practices that increase the quality and efficiency of... Read More
GreenStockNews
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, has agreed to partner with Sphe re Health – a physician-founded employee benefits provider targeting treatments for people with severe mental illness – to collect and analyze... Read More
GreenStockNews
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) ("MindMed" or the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that its board of directors has appointed Mr. Andreas Krebs and Ms. Carol Vallone as directors of the Company, effective immediately. Mr.... Read More
GreenStockNews
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce the addition of Bryan L. Roth , MD, PhD to its Scientific Advisory Board. Dr. Roth has spent over 30 years studying molecular neuropharmacology. He is... Read More
GreenStockNews
MindMed (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that Robert Barrow , Chief Executive Officer of MindMed, will be speaking at the Benzinga Healthcare Small Cap Conference, taking place on September 29-30, 2021 . Barrow... Read More
GreenStockNews
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that Dr. Matthias Liechti presented data from several ongoing studies at the INSIGHT Conference in Berlin, Germany . These investigator-initiated... Read More
GreenStockNews
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, today announces that Robert Barrow , Chief Executive Officer of MindMed, will participate in the following investor conferences: Advances in Mental Health Virtual Conference... Read More
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that Robert Barrow , Chief Executive Officer of MindMed, will present at the virtual H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021 . Members of management will also be available to speak with institutional... Read More
GreenStockNews
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that its Chief Medical Officer, Daniel R. Karlin , MD MA, will co-chair the 8th annual Mobile in Clinical Trials Conference , which will be held... Read More
GreenStockNews
MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, and BioXcel Therapeutics, Inc. ("BioXcel"), a leading clinical-stage biopharmaceutical company, announce the publication of BioXcel's International Patent Application No. PCT/US2020/051256... Read More
GreenStockNews
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, has joined the Critical Path Institute's ("C-Path's") Patient-Reported Outcome (PRO) Consortium to assist in the development of new approaches to advance medical innovation... Read More
NEW YORK , Aug. 12, 2021 /CNW/ -- MindMed (Nasdaq: MNMD), (NEO: MMED), (DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, has announced its quarterly financial results for the quarter ended June 30, 2021 . Q2 2021 Financial Highlights (in USD) Total assets as of June 30, 2021 were $194 million , including $157 million in cash Net Cash Used in Operating Activities of $12 million for the quarter... Read More
GreenStockNews
MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, announces the addition of Robert H. Dworkin , Ph.D. to its Scientific Advisory Board. Dr. Dworkin has spent over 35 years conducting clinical research on pain. He is currently Professor of Anesthesiology and... Read More
GreenStockNews
MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, announced today that it will participate in and financially support the Digital Medicine Society's (DiMe) Digital Health Measurement Collaborative Community (DATAcc), an effort to develop best practices and... Read More
MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce the start of a Phase 1 clinical trial to assess the safety, pharmacokinetics and pharmacodynamics of DMT, a naturally occurring psychedelic substance and an active ingredient in ayahuasca. The outcome of this Phase 1 clinical trial is expected to facilitate potential future Phase 2... Read More
GreenStockNews
MindMed (NASDAQ: MNMD, NEO: MMED, DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that MindMed's Chief Executive Officer, Robert Barrow , will be leading a roundtable discussion at Cowen's Psychedelics & Novel Mechanisms in Neuropsychiatry Virtual Summit. The event is set... Read More
GreenStockNews
MindMed (Nasdaq: MNMD, NEO: MMED, DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, and Datavant, Inc. (" Datavant "), a leader in helping healthcare organizations safely connect their data, announced a partnership through which MindMed will use Datavant's privacy-protecting technology to link... Read More
GreenStockNews
MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a leading psychedelic-inspired medicine company announced that effective Friday, June 25th, 2021 , MindMed has been added to the FTSE Russell 3000 ® index which measures the performance of the largest 3,000 US companies. The annual Russell indexes reconstitution process captures... Read More
MindMed (Nasdaq: MNMD) (NEO: MMED) (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, has announced the addition of Dr. Maurizio Fava , a world-leading expert in psychiatry and psychiatric clinical trials from Massachusetts General Hospital and the Harvard Medical School to the Company's Scientific Advisory Board. Dr. Fava obtained his MD from the University of Padova School of... Read More
GreenStockNews
MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, has announced the addition of Dr. Peter Bergethon , a world-leading expert in neurology, digital medicine, and central nervous system (CNS) drug development to the Company's Scientific Advisory... Read More
OTCStockReview.com News Commentary Jim Cramer discussed psychedelics on his June 15, 2021 program and said, “The science behind using psychedelics to treat mental health disorders and addiction is compelling." He also said big drug companies tried, and failed, to treat major depression. Those of us who have been in psychedelic stocks for the last year and a half heard him say that the big money is waking up! Investors in... Read More
GreenStockNews
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading clinical-stage pharmaceutical company and pioneer in the field of psychedelic inspired medicines, announces that J.R. Rahn, the Company's co-founder and chief executive officer, is stepping down as chief executive officer and a... Read More
GreenStockNews
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) ("MindMed" or the "Company") is pleased to announce that each of the resolutions put before the annual and special meeting of shareholders held today (the "Meeting") was passed by the requisite majority of shareholders. As described in the Company's management... Read More

COPYRIGHT ©2022 GREEN STOCK NEWS